Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 4, 2016, Pages 456-463

  Heebøll, Sara ^a   Kreuzfeldt, Martin ^a   Hamilton Dutoit, Stephen ^a   Kjær Poulsen, Marianne ^a   Stødkilde Jørgensen, Hans ^a   Møller, Holger Jon ^a   Jessen, Niels ^a   Thorsen, Kasper ^a   Kristina Hellberg, Ylva ^b   Bønløkke Pedersen, Steen ^a   Grønbæk, Henning ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Anti inflammatory agents; antioxidants; non alcoholic fatty liver disease; non alcoholicsteatohepatitis; resveratrol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CD163 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA1; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEME OXYGENASE 1; INSULIN; LIPID; PLACEBO; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIOXIDANT; STILBENE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAT CONTENT; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; INSULIN SENSITIVITY; LEUKOPENIA; LIVER BIOPSY; LIVER INJURY; LYMPHOCYTOPENIA; MALE; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; DOUBLE BLIND PROCEDURE; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDY;

ANTIOXIDANTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; STILBENES;

EID: 84955125942     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1107620     Document Type: Article

References (30)

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-690
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285
3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344
4. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384
5. Dudekula A, Rachakonda V, Shaik B, et al. Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS One. 2014;9:e111808
6. Chachay VS, Kirkpatrick CM, Hickman IJ, et al. Resveratrolpills to replace a healthy diet? Br J Clin Pharmacol. 2011;72:27-38
7. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337-342
8. Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev. 2010;131:261-269
9. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612-622
10. Heebøll S, Thomsen KL, Pedersen SB, et al. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol. 2014;6:188-198
11. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41: 1313-1321
12. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751-1759
13. Kazankov K, Møller HJ, Lange A, et al. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children. Pediatr Obes. 2015;10: 226-233
14. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685
15. Suzuki A, Lymp J, Sauver JS, et al. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 2006;26:1209-1216
16. Heebøll S, Thomsen KL, Clouston A, et al. Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacol Res. 2015;9596C:34-41
17. Faghihzadeh F, Adibi P, Rafiei R, et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34:837-843
18. Chachay VS, Macdonald GA, Martin JH, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12: 2092-2103
19. Poulsen MM, Vestergaard PF, Clasen BF, et al. Highdose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebocontrolled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62: 1186-1195
20. Yoshino J, Conte C, Fontana L, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012;16:658-664
21. Chen S, Zhao X, Ran L, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015;47: 226-232
22. de Ligt M, Timmers S, Schrauwen P. Resveratrol and obesity: can resveratrol relieve metabolic disturbances? Biochim Biophys Acta. 2015;1852:1137-1144
23. Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, et al. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12:497-501
24. Tang PC, Ng YF, Ho S, et al. Resveratrol and cardiovascular health-promising therapeutic or hopeless illusion? Pharmacol Res. 2014;90:88-115
25. Patel KR, Andreadi C, Britton RG, et al. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med. 2013;5:205ra133
26. Liu Y, Ma W, Zhang P, et al. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. 2015;34:27-34
27. Ørnstrup MJ, Harsløf T, Kjær TN, et al. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2014;99:4720-4729
28. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109-1122
29. Zhou M, Wang S, Zhao A, et al. Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice. J Proteome Res. 2012;11:4961-4971
30. Cottart CH, Nivet-Antoine V, Beaudeux JL. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. 2014;58:7-21